General Questions

1.Where do shares of Geron trade and what is the ticker symbol?
2.When was Geron incorporated?
3.What is Geron's fiscal year-end?
4.Do you anticipate paying a dividend?
5.Does Geron have a DRIP (Dividend Reinvestment Program)?
6.Can I purchase or sell my shares directly through Geron?
7.I have lost my stock certificates and my broker cannot assist me. Who do I talk with to resolve this problem?
8.What do I do if my address has changed?
9.How do I get an investor packet?
10.Who can I contact if I have questions or need more information?
11.Who can I contact if I am a member of the media?
12.Can I be added to Geron’s mailing list?

Clinical Pipeline

13.What clinical trials are underway at Geron?
14.Where are the trials being conducted?
15.How can I learn more about Geron’s clinical trials?
16.Are any of these programs partnered?
17.What happened to the stem cell programs?
18.What happened to the stem cell clinical trial in spinal cord injury?
1.Where do shares of Geron trade and what is the ticker symbol?
 Geron common stock trades on the Nasdaq Global Stock Market under the ticker symbol GERN.

2.When was Geron incorporated?
 Geron was incorporated in Delaware in November 1990.

3.What is Geron's fiscal year-end?
 Geron is on a calendar year-end schedule.

4.Do you anticipate paying a dividend?
 The company has not paid any dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future.

5.Does Geron have a DRIP (Dividend Reinvestment Program)?
 No, Geron has not paid and does not intend to pay dividends in the foreseeable future and therefore does not have a dividend reinvestment program.

6.Can I purchase or sell my shares directly through Geron?
 No, Geron does not have a direct stock purchase program. You will need to contact your broker or purchase shares through an online stock transaction service.

7.I have lost my stock certificates and my broker cannot assist me. Who do I talk with to resolve this problem?
 Geron’s stock transfer agent:
Computershare Trust Company
250 Royall Street,
Canton, MA 02021
Tel: 1-800-962-4284 or Fax: 303-262-0700
www.computershare.com

8.What do I do if my address has changed?
 If your shares are held in your name, you may contact Computershare Trust Company as indicated above. If your shares are held in Street name, you must contact your broker to update your address.

9.How do I get an investor packet?
 Please click here to request an investor packet.

10.Who can I contact if I have questions or need more information?
 Please contact Investor Relations at 650-473-7765 or via email at investor@geron.com.

11.Who can I contact if I am a member of the media?
 Anna Krassowska
Geron Corporation
230 Constitution Drive
Menlo Park, CA 94025
Tel: 650-473-7765
Email: media@geron.com

12.Can I be added to Geron’s mailing list?
 We do not maintain a postal mailing list for materials. However, if you would like to join our email distribution list for press releases, please send your name and email address to investor@geron.com.

13.What clinical trials are underway at Geron?
 We are sponsoring six Phase 2 clinical trials:
  • Imetelstat, our lead telomerase inhibitor, is currently being evaluated in four Phase 2 clinical oncology studies for the non-small cell lung cancer, breast cancer, essential thrombocythemia and multiple myeloma.
  • GRN1005, an LRP-directed peptide-drug conjugate, is being evaluated in two Phase 2 clinical trials, one for brain metastases arising from non-small cell lung cancer and the other for brain metastases arising from breast cancer.

14.Where are the trials being conducted?
 Geron’s clinical trials are being conducted in the United States, Canada, Germany and Switzerland. Please visit our clinical trials pages for information on our clinical trials.

15.How can I learn more about Geron’s clinical trials?
 Please visit our clinical trials pages for information on our clinical trials.

16.Are any of these programs partnered?
 Imetelstat, our telomerase inhibitor is not partnered. GRN1005, our LRP-directed peptide drug conjugate, was in-licensed from Angiochem, Inc. for worldwide exclusive rights.

17.What happened to the stem cell programs?
 Geron is no longer funding development of the stem cell programs and is seeking partners for these novel assets. To explore licensing or other collaborative opportunities for the stem cell programs, please contact the Corporate Development group at (+1) 650-473-7727 or CorpDev@geron.com.
  • Click here for more information about the stem cell programs.

18.What happened to the stem cell clinical trial in spinal cord injury?
 Geron closed the Phase 1 clinical trial of GRNOPC1 for spinal cord injury to further patient enrollment in November 2011. We will continue to follow all enrolled patients accruing data and updating the FDA and the medical community on their progress.



RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Close Video
Close Window
Close
Form content here please :)